Purpose: To assess the ability of (N-[N-[(S) F-DCFBC PET images were fused by using software registration; imaging findings were correlated with histology, and uptake of 18 F-DCFBC in tumors was compared with uptake in benign prostatic hyperplasia nodules and normal peripheral zone tissue using the 80% threshold SUVmax. Results: A total of 25 tumor foci (mean size, 1.8 cm; median size, 1.5 cm; range, 0.6-4.7 cm) were histopathologically identified in 13 patients. Sensitivity rates of 18 F-DCFBC PET/CT and mpMRI were 36% and 96%, respectively, for all tumors. For index lesions, the largest tumor with highest Gleason score, sensitivity rates of 18 F-DCFBC PET/CT and mpMRI were 61.5% and 92%, respectively. The average SUVmax for primary prostate cancer was higher (5.8 ± 4.4) than that of benign prostatic hyperplasia nodules (2.1 ± 0.3) or that of normal prostate tissue (2.1 ± 0.4) at 1 hour postinjection (P = 0.0033). Conclusions: The majority of index prostate cancers are detected with 18 F-DCFBC PET/CT, and this may be a prognostic indicator based on uptake and staging. However, for detecting prostate cancer with high sensitivity, it is important to combine prostate-specific membrane antigen PET/CT with mpMRI.
P
rostate cancer is the most common cancer type in men and is the second leading cause of cancer-related deaths in men in the United States. 1 Until recently, diagnosis was based on an elevated prostate-specific antigen (PSA) value and a random biopsy of the prostate. Multiparametric MRI (mpMRI) has improved lesion detection in prostate cancer care by identifying suspicious lesions suitable for MRI-transrectal ultrasound (TRUS) fusion-guided biopsy. However, there is a considerable false-positive rate for mpMRI, and there is still no robust method to distinguish clinically significant cancers from indolent cancers other than biopsy. Moreover, local staging is relatively limited with mpMRI. A molecular imaging technique that could reliably identify intermediate-and high-risk cancers and stage them without detecting indolent cancers is needed.
Targeted imaging with PET/CT has been extensively studied for more than a decade in order to address this, and several tracers have been proposed, such as 18 F-FDG, 11 C-acetate, 18 F-choline, and 18 F-FACBC (fluciclovine); however, almost all of these tracers have been shown to have limited use in the setting of localized prostate cancer because they are taken up in benign conditions as well as malignancies and have a low sensitivity for extraprostatic disease. A major issue with these agents is a high false-positive rate due to uptake in benign prostate hyperplasia (BPH). [2] [3] [4] Prostate-specific membrane antigen (PSMA) is a transmembrane protein that has been shown to be overexpressed in more aggressive prostate cancers. 5 Recently, there has been growing interest in targeted imaging of PSMA using one of several PSMA-targeted agents that are labeled with 68 Ga (eg, 68 Ga-PSMA-HBED-CC) or 18 F (eg, 18 F-DCFBC and 18 F-DCFPyL). 6 Several research groups have reported improved prostate cancer detection in patients with biochemical recurrence and metastatic prostate cancer with radiolabeled PSMA-targeted PET tracers. However, experience is still limited in PSMA PET imaging for localized primary prostate cancer. 6, 7 The aim of our study was to assess the ability of (N-[N-
, a PSMA-targeted PET agent, to detect localized prostate cancer lesions in correlation with mpMRI and histopathology.
METHODS

Study Design and Patient Population
This was a Health Insurance Portability and Accountability Act of 1996-compliant, prospective, single-institution study, approved by the local institutional review board with written informed consent, under a US Food and Drug Administration-approved Investigational New Drug Application (NCT02190279). Inclusion criteria included patients with histologically proven prostatic adenocarcinoma. Exclusion criteria were contraindications to PET/CT scan or MRI, prior androgen deprivation therapy, or histopathology information that was not available.
Between July 2014 and April 2016, 17 patients signed the consent form, and 16 of them (mean age, 64 years; range, 51-74 years) underwent 18 F-DCFBC PET/CT imaging. One patient refused the tracer injection after signing the consent form and was excluded. All patients had mpMRI of the prostate at 3 T within 3 months of the PET/CT imaging. Following imaging, all patients underwent either MRI/TRUS fusion-guided biopsy or roboticassisted laparoscopic radical prostatectomy. Overall, there were 13 evaluable data sets for analysis; 3 patients were excluded from analysis, because of prior focal laser ablation therapy (n = 1), prior brachytherapy (n = 1), and lack of histopathology confirmation tissue (n = 1). 
Data Analysis Histopathologic Analysis
All patients underwent MRI/TRUS fusion-guided biopsy or robotic-assisted laparoscopic radical prostatectomy and lymph node (LN) dissection. The prostatectomy specimens were fixed in formalin for 24 to 48 hours at room temperature. After fixation, the seminal vesicles were removed, and the gland was sliced, in axial orientation using a customized 3-dimensional printed mold, based on the preoperative MRI. 8 Each slice was sequentially labeled and fixed for a further period of 24 to 48 hours, processed, and paraffin embedded as a whole mount. The tissue blocks were stained with hematoxylin-eosin. The resulting whole-mount specimens were correlated with MRI and PET/CT imaging.
A pathologist (M.J.M., with 30 years of experience) who was blinded to the imaging results independently reviewed the surgical specimens assessing for the presence of tumor, Gleason score, extracapsular extension, and seminal vesicle invasion. For each patient, a dominant/index tumor (largest tumor with highest Gleason score) was determined.
Imaging Data and Histopathology Correlation
PET/CT images were registered and fused in the same plane as the MRI using commercial software (MIM 5.4 software; MIM Software Inc, Cleveland, Ohio); the transmission CT was used to initially fuse the images with MRI using the pelvic bones as fiducial markers. As the PET and CT were already registered to each other, PET data were similarly brought into the MRI/CT "space," resulting in the registration of the MRI and PET. Manual adjustments were necessary in all patients to accurately register the MRI and PET images to account for prostate motion and deformation.
Imaging Analysis Visual Qualitative Analysis for Tumor Detection
One nuclear medicine physician (E.M., with 6 years of experience in PET/CT imaging), blinded to MRI and histopathology results, prospectively assessed the 18 F-DCFBC PET/CT scans. One radiologist (B.T., with 9 years of experience in prostate MRI), blinded to histopathology results, prospectively assessed the MRI scans. A lesion-based analysis was performed for each patient.
Lesion-Based Analysis
On 60-and 120-minute postinjection (p.i.) 18 F-DCFBC PET images, volumes of interest were created for each visually identified focus of 18 F-DCFBC uptake (greater than adjacent background), encompassing each entire visualized lesion. Time-activity curves were generated from the dynamic PET data (obtained in the first 45 minutes). PET data were reconstructed into 25 frames using the following timing sequence: 4 time frames of 30-second duration, 8 time frames of 60-second duration, 10 time frames of 120-second duration, and 3 time frames of 300-second duration. Contours were drawn on the registered MR scans delineating volumes containing tumor, BPH, and normal tissue and transferred to the dynamic scan. The dynamic scan was spatially registered with the MR scan on which the contour regions of tumor, BPH, and normal tissue were originally drawn. Additional contours were drawn on the iliac and bladder region directly on the dynamic scan, the former to obtain the input function for the pharmacokinetic modeling and the latter to evaluate the effects of the bladder activity on the prostate region over time. Time-activity curve results of For the MRI analysis, the reader, who was blinded to the PET results, used the prostate imaging-reporting and data system version 2 criteria to delineate focal lesions. 9 
Retrospective Quantitative Analysis
On fused PET/MRI true-positive (TP) tumor foci, BPH nodules and normal prostate tissue were contoured in order to compare SUVmax within these 3 entities.
Staging Analysis
Clinical and pathologic TNM staging was done in each patient using the American Joint Committee on Cancer document (https:// cancerstaging.org/references-tools/quickreferences/documents/ prostatesmall.pdf).
Statistical Analysis
For visual qualitative analysis, the sensitivities and positive predictive values (PPVs) of both mpMRI and 18 F-DCFBC PET/ CT were calculated. SUVmax measurements of 18 F-DCFBC PET/ CT imaging were obtained in tumor and nontumor regions, including BPH and normal prostate tissue, and compared using a 1-way analysis of variance. In addition, the 18 F-DCFBC SUVmax was correlated with tumor size, histopathologic Gleason score, and PSA values, using the Spearman rank correlation. The 2-sample Wilcoxon test was used to compare SUVmax between those with a low Gleason score versus those with a high Gleason score (3 + 4 or lower vs 4 + 3 or higher) or between those with low PSA level and those with a high PSA level (≤10 vs >10 ng/mL); results are presented as mean ± 1 SD (P < 0.05 was considered to represent a significant difference).
RESULTS
Clinical Findings
The evaluable study population consisted of 13 prostate cancer patients (mean age, 62.8 years; range, 51-74 years) who underwent TRUS/MRI fusion-guided biopsy (n = 9) or radical prostatectomy (n = 4). Table 1) . Four patients underwent radical prostatectomy with LN dissection, which revealed metastatic nodal involvement in 1 patient. Clinical and TNM staging of the patient cohort is presented in Table 2 .
Tumor Detection Rates of 18 
F-DCFBC PET/CT and mpMRI
Lesion-Based Analysis
The lesion-based analysis for 18 F-DCFBC PET revealed 9 TP tumor sites (mean size, 2.6 cm; median size, 1.8 cm; range, 1.4-4.7 cm) ( Figs. 1 and 2 ) and 18 false-negative (FN) sites (mean size, 1.2 cm; median size, 1.3 cm; range, 0.6-2.1 cm), with no falsepositive sites, which resulted in a sensitivity of 36% (9/25) but a PPV of 100% (9/9). For mpMRI, 24 sites were TP (mean size, 1.8 cm; median size, 1.5 cm; range, 0.6-4.7 cm), 1 was FN (0.6 cm in diameter), and 3 were false positive for tumor, resulting in a sensitivity of 96% (24/25) and a PPV of 89% (24/27). Sensitivity rates for index lesions were 92% (12/13) for mpMRI and 61.5% (8/13) for 18 F-DCFBC PET.
Quantitative Analysis
At 1 hour p.i., the average SUVmax of the histopathologically confirmed tumors (outlined on the MRI registered to PET) (Fig. 3) . Moderate correlation was observed between SUVmax values and Gleason scores (r = 0.6); however, there was no statistically significant difference between the SUVmax for tumors with lower Gleason score and higher Gleason scores (P = 0.12) (Fig. 4) . No significant correlation was seen between SUVmax and PSA levels (r = 0.30). Time-activity curve results are presented in the supplement material (http://links.lww.com/CNM/ A91); however, dynamic evaluation of the data did not improve detection rates.
TNM Staging With 18 F-DCFBC PET/CT
Staging was performed pathologically in 4 patients and clinically in 9 patients. 18 F-DCFBC PET/CT staging was performed in 8 patients with positive agent uptake. Among the staged 8 patients, in 4 patients 18 F-DCFBC PET/CT understaged tumor burden (n = 2 tumor, n = 1 nodal, n = 1 both tumor and nodal). MRI performed correct T staging in 10 of 12 patients (n = 1 patient could not be T staged at MRI because there was no visible lesion on MRI); for 18 F-DCFBC PET/CT, T staging was available in 8 patients, of whom 5 were correctly T staged (Table 2) .
DISCUSSION
Multiparametric MRI with targeted prostate biopsy enables accurate detection of prostate cancer. 10 However, current diagnostic techniques, including mpMRI, do not accurately assess prostate cancer aggressiveness or accurately perform local staging. Accurate depiction of the location, stage, and aggressiveness of index tumors may enable improved management of prostate cancer. 11 Prostatespecific membrane antigen-targeted PET imaging is a promising new approach to accomplish this goal because PSMA expression is documented to correlate with prostate cancer aggressiveness. F-DCFBC PET/CT to accurately detect large-volume Gleason 3 + 4 and higher-grade prostate cancers in 13 patients. Moreover, they reported a moderate correlation between SUV and tumor Gleason grades, as we also confirmed in the current study. 7 Moreover, PSMA-targeted agents appear to differentiate benign prostate hyperplasia from prostate cancer with more than 2-fold higher uptake in the latter observed in this study. Similar findings have been reported by Fendler et al 13 using 68 Ga-PSMA-HBED-CC PET/CT in 21 patients. They identified a significant SUV difference between prostate cancer and benign prostate tissue (11.8 ± 7.6 vs 4.9 ± 2.9) with a similar more than 2-fold greater uptake in cancer. This is not true of other agents we have studied in a similar population with 11 C-acetate and However, it is unclear whether PSMA PET/CT is superior to mpMRI for detecting clinically significant prostate cancer. In a study of 20 patients who underwent both mpMRI and 68 Ga-PSMA-HBED-CC PET, the sensitivity, specificity, PPV, and negative predictive value for mpMRI and 68 Ga-PSMA-HBED-CC PET were approximately equal (for mpMRI 44%, 94%, 81%, and 76%, and for 68 Ga-PSMA-HBED-CC PET 49%, 95%, 85%, and 88%, respectively). Based on these low sensitivity values in both imaging techniques, the authors suggest potential complementarity of mpMRI and PSMA PET imaging.
14 However, this is different from what we observed in the current study, where 18 F-DCFBC PET imaging detected only 61.5% of index lesions, whereas mpMRI detected 95% of index lesions. The majority of the missed index lesions were Gleason 3 + 4 (4/6), but one was Gleason 4 + 4, and another was Gleason 4 + 3. Multiparametric MRI was much more sensitive especially for lesions less than 1 cm in dimension compared with 18 F-DCFBC PET/CT imaging. Whereas mpMRI was more sensitive in tumor detection, 18 F-DCFBC PET exhibited a higher PPV (100%). Thus, a positive 18 F-DCFBC PETwith a positive mpMRI is highly likely to yield a clinically significant index lesion. This may be useful in some patients in whom biopsy poses severe risks (eg, prior sepsis requiring hospitalization or patients without a rectum).
Another potential utility of PSMA-targeted PET imaging could be staging prostate cancer especially when they are high risk. Budaus Ga-PSMA PET/CT for LN metastasis detection were 33.3%, 100%, 100%, and 69.2%, respectively. 15 In our cohort, we compared the overall TNM staging of 18 F-DCFBC PET/CTwith clinical and pathologic (whenever available) staging. Among 8 patients in whom a TP tumor was detected by 18 F-DCFBC PET/CT imaging, TNM staging showed concordance with clinical or pathologic staging in 4 patients; whereas in the other 4 patients, 18 F-DCFBC PET/CT imaging understaged including 1 FN node, 1 FN T3a and N1 staging, 1 FN seminal vesicle invasion, and 1 FN T2c staging because of a missed intraprostatic lesion in the contralateral lobe. Although the staging results were limited in number, these preliminary findings are consistent with a relatively low accuracy for staging compared with surgery. This is likely due to the small volume of such nodal metastases, but this finding should be explored in more detail before PSMA PET/CT is introduced as a staging tool. It is also possible that second-generation agents such as 18 F-DCFPyl may perform better because there are both higher affinity and decreased background with these agents. 16, 17 Our study has several limitations; first, our study included only a limited number of patients and tumors. Second, we fused PET and MRI and histopathology data using a semiautomated mutual information technique followed by minor manual adjustments. This approach does not account for prostate deformation because of the endorectal coil or from the deformation due to pathology fixation of the specimen, which could cause some misregistration. We do not believe this caused a problem in the analysis because we were always able to match lesions visually. Finally, 18 F-DCFBC demonstrated a moderate amount of background blood pool activity, which F-DCFBC uptake than BPH or normal prostate areas, at 1 hour (P = 0.0033) and at 2 hours (P = 0.012) p.i.
was also reported by Rowe et al 7 and potentially limits the sensitivity of this agent in soft tissues by decreasing the tumor-to-background ratio, which can ultimately limit the detection of cancer. The secondgeneration compound of 18 F-labeled PSMA is 18 F-DCFPyL, which has been reported to have less background blood pool activity, and more tumor-specific uptake 18 is likely to perform better. We will shortly begin testing this agent in a clinical trial.
CONCLUSIONS
18
F-DCFBC PET/CT has lower sensitivity than mpMRI in detecting prostate cancer but has a higher PPV, suggesting a potential role in patients at high risk of biopsy. It clearly identifies cancers in comparison to BPH. There is a moderate correlation of uptake and Gleason grade. Dynamically acquired PET data do not add sensitivity or specificity to the examination. Limited data suggest that PSMA PET tends to understage prostate cancer. The second generation of this agent, 18 F-DCFPyL, may reduce some of these limitations.
